Mezzion & FUEL-2: A New Chapter of Hope with John Pressor, Margaret Sarah Alexander, and Meg Didier

Today, we’re joined by members of Mezzion, a pharmaceutical company focused on improving outcomes for those living with single ventricle heart conditions. In our conversation with John, Margaret Sarah, and Meg, we learn more about their mission to bring hope to the CHD community through their FUEL-2 study.FUEL-2 is exploring a potential new medication called udenafil, designed to help children and teens who have undergone the Fontan procedure. The study is looking at whether this treatment can improve energy levels, exercise capacity, and daily functioning, while also evaluating its safety.Join us as they share more about Mezzion’s work, the population they serve, and how studies like FUEL-2 could make a meaningful difference for the single ventricle community.https://mezzion.com/https://www.fuel2study.com/https://www.linkedin.com/company/mezzionIf you or someone you know would like to be part of the podcast you can message both Meagan and Amy at:  candidhearts25@gmail,comFind our journey’s on Facebook:My HLHS Diary- Amy Erhart CunninghamMy HLHS Story- Meagan Houpt